Esperion's (ESPR) Drugs Get EU Nod for Lowering Heart Risk

Zacks05-24

Esperion Therapeutics, Inc. ESPR and partner Daiichi Sankyo Europe GmbH announced that the European Commission (EC) has approved a label update for its drugs Nilemdo (bempedoic acid) and Nustendi for ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2437791116?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/sb.6qRd7FfGt7.wCjWz2vw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/675c0ae70cb5036ad2ceb9062f13afc2","is_english":true,"pubTime":"2024-05-24 00:11","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2437791116","market":"us","top_or_hot":-1,"title":"Esperion's (ESPR) Drugs Get EU Nod for Lowering Heart Risk","media":"Zacks","content":"<div>\n<p>Esperion Therapeutics, Inc. ESPR and partner Daiichi Sankyo Europe GmbH announced that the European Commission (EC) has approved a label update for its drugs Nilemdo (bempedoic acid) and Nustendi for ...</p>\n\n<a href=\"https://finance.yahoo.com/news/esperions-espr-drugs-eu-nod-161100476.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Esperion's (ESPR) Drugs Get EU Nod for Lowering Heart Risk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEsperion's (ESPR) Drugs Get EU Nod for Lowering Heart Risk\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-05-24 00:11 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/esperions-espr-drugs-eu-nod-161100476.html><strong>Zacks</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Esperion Therapeutics, Inc. ESPR and partner Daiichi Sankyo Europe GmbH announced that the European Commission (EC) has approved a label update for its drugs Nilemdo (bempedoic acid) and Nustendi for ...</p>\n\n<a href=\"https://finance.yahoo.com/news/esperions-espr-drugs-eu-nod-161100476.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MRNS","symbol_name":"Marinus Pharmaceuticals","start_time":0,"source_url":"https://finance.yahoo.com/news/esperions-espr-drugs-eu-nod-161100476.html","article_id":"2437791116","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/sb.6qRd7FfGt7.wCjWz2vw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/675c0ae70cb5036ad2ceb9062f13afc2"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2437791116","pubTimestamp":1716480660,"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"Following the label expansion in Europe, Nilemdo and Nustendi became the first and only treatments for lowering low-density lipoprotein cholesterol , also known as bad cholesterol, approved for primary and secondary prevention of CV events.Additionally, the updated labels support the use of Nilemdo and Nustendi either alone or in combination with statins.Please note that Nustendi is a fixed-dose combination of bempedoic acid and ezetimibe.The latest EC approval was based on positive data from the phase III CLEAR Outcomes study. Data from the same showed that treatment with Nilemdo and Nustendi led to a 13% reduction in the relative risk of major adverse CV events defined as a four-component composite of death from CV causes, non-fatal myocardial infarction, non-fatal stroke or coronary revascularization.The decision from the EC was expected as the Committee for Medicinal Products for Human Use  recommended the approval for the label update of both Nilemdo and Nustendi as treatments to ","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"MRNS":"Marinus Pharmaceuticals","EU":"ENCORE ENERGY CORP","NERV":"Minerva Neurosciences","BK4087":"商业印刷","EC":"哥伦比亚国家石油","ESPR":"Esperion Therapeutics Inc.","BK4156":"煤与消费用燃料","CHMP":"冠军工业","BK4139":"生物科技","KRYS":"Krystal Biotech Inc.","BK4201":"综合性石油与天然气企业","BK4007":"制药"},"translate_title":"Esperion（ESPR）降低心脏病风险获得欧盟认可","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CHMP":1,"EC":1,"ESPR":1,"EU":1,"KRYS":1,"MRNS":1,"NERV":1},"content_text":"Esperion Therapeutics, Inc. ESPR and partner Daiichi Sankyo Europe GmbH announced that the European Commission (EC) has approved a label update for its drugs Nilemdo (bempedoic acid) and Nustendi for the treatment of hypercholesterolemia and to reduce the risk of adverse cardiovascular (CV) events.\nHypercholesterolemia indicates elevated levels of cholesterol in the blood.\nFollowing the label expansion in Europe, Nilemdo and Nustendi became the first and only treatments for lowering low-density lipoprotein cholesterol (LDL-C), also known as bad cholesterol, approved for primary and secondary prevention of CV events.\nAdditionally, the updated labels support the use of Nilemdo and Nustendi either alone or in combination with statins.\nPlease note that Nustendi is a fixed-dose combination of bempedoic acid and ezetimibe.\nThe latest EC approval was based on positive data from the phase III CLEAR Outcomes study. Data from the same showed that treatment with Nilemdo and Nustendi led to a 13% reduction in the relative risk of major adverse CV events defined as a four-component composite of death from CV causes, non-fatal myocardial infarction, non-fatal stroke or coronary revascularization.\nThe decision from the EC was expected as the Committee for Medicinal Products for Human Use (CHMP) recommended the approval for the label update of both Nilemdo and Nustendi as treatments to reduce LDL-C and CV risk in March 2024.\nShares of Esperion have plunged 20.4% year to date compared with the industry’s decline of 7.4%.\nImage Source: Zacks Investment Research\nPer the company, despite receiving treatments with statins, around 80% of patients do not reach the guideline-recommended LDL-C goals and remain at higher risk of a heart attack or stroke.\nHence, with the updated label for Nilemdo and Nustendi that covers both primary and secondary prevention, statin-intolerant patients in need of additional treatment can be addressed better, improving CV care throughout Europe.\nNilemdo and Nustendi are marketed as Nexletol and Nexlizet, respectively, in the United States. The drugs are already approved for treating elevated LDL-C and CV risk reduction in the United States.\nThe FDA approved the label expansions for Nexletol tablets and Nexlizet tablets to include indications for CV risk reduction and expanded LDL-C lowering in both primary and secondary prevention patients in March.\nZacks Rank & Stocks to Consider\nEsperion currently carries a Zacks Rank #3 (Hold).\nSome better-ranked stocks in the healthcare sector are Krystal Biotech, Inc. KRYS, Marinus Pharmaceuticals, Inc. MRNS and Minerva Neurosciences, Inc. NERV, each carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.\nIn the past 60 days, estimates for Krystal Biotech’s 2024 earnings per share have improved from $1.61 to $2.06. Earnings per share estimates for 2025 have improved from $3.69 to $4.33. Year to date, shares of KRYS have surged 36.5%.\nKRYS’s earnings beat estimates in two of the trailing four quarters and missed the same on the remaining two occasions, the average negative surprise being 21.46%.\nIn the past 60 days, estimates for Marinus Pharmaceuticals’ 2024 loss per share have narrowed from $2.44 to $1.87, while loss per share estimates for 2025 have narrowed from $1.97 to 90 cents. Year to date, shares of MRNS have plunged 88.2%.\nMRNS’s earnings beat estimates in two of the trailing four quarters, met the same once and missed the same once, the average surprise being 3.27%.\nIn the past 60 days, estimates for Minerva Neurosciences’ 2024 loss per share have narrowed from $3.57 to $1.89. Loss per share estimates for 2025 have narrowed from $4.54 to $3.60. Year to date, shares of NERV have declined 59.4%.\nNERV’s earnings beat estimates in one of the trailing four quarters while missing the same in the remaining three occasions, the average negative surprise being 54.43%.\nWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report\nMinerva Neurosciences, Inc (NERV) : Free Stock Analysis Report\nEsperion Therapeutics, Inc. (ESPR) : Free Stock Analysis Report\nMarinus Pharmaceuticals, Inc. (MRNS) : Free Stock Analysis Report\nKrystal Biotech, Inc. (KRYS) : Free Stock Analysis Report\nTo read this article on Zacks.com click here.\nZacks Investment Research","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.24.0","shortVersion":"4.24.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2437791116"}